JP2021513990A5 - - Google Patents

Info

Publication number
JP2021513990A5
JP2021513990A5 JP2020543847A JP2020543847A JP2021513990A5 JP 2021513990 A5 JP2021513990 A5 JP 2021513990A5 JP 2020543847 A JP2020543847 A JP 2020543847A JP 2020543847 A JP2020543847 A JP 2020543847A JP 2021513990 A5 JP2021513990 A5 JP 2021513990A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
unit
group
needed
Prior art date
Application number
JP2020543847A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019164987A5 (https=
JP2021513990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018825 external-priority patent/WO2019164987A1/en
Publication of JP2021513990A publication Critical patent/JP2021513990A/ja
Publication of JPWO2019164987A5 publication Critical patent/JPWO2019164987A5/ja
Publication of JP2021513990A5 publication Critical patent/JP2021513990A5/ja
Priority to JP2023116253A priority Critical patent/JP2023129495A/ja
Pending legal-status Critical Current

Links

JP2020543847A 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート Pending JP2021513990A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023116253A JP2023129495A (ja) 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633059P 2018-02-20 2018-02-20
US62/633,059 2018-02-20
PCT/US2019/018825 WO2019164987A1 (en) 2018-02-20 2019-02-20 Hydrophobic auristatin f compounds and conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116253A Division JP2023129495A (ja) 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2021513990A JP2021513990A (ja) 2021-06-03
JPWO2019164987A5 JPWO2019164987A5 (https=) 2022-03-01
JP2021513990A5 true JP2021513990A5 (https=) 2022-03-01

Family

ID=65904522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543847A Pending JP2021513990A (ja) 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート
JP2023116253A Pending JP2023129495A (ja) 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023116253A Pending JP2023129495A (ja) 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート

Country Status (12)

Country Link
US (2) US11857565B2 (https=)
EP (1) EP3755707A1 (https=)
JP (2) JP2021513990A (https=)
KR (1) KR20200122351A (https=)
CN (1) CN111989339A (https=)
AU (1) AU2019225845B2 (https=)
CA (1) CA3090805A1 (https=)
IL (1) IL276546B2 (https=)
MX (1) MX2020008267A (https=)
SG (1) SG11202007540SA (https=)
TW (1) TWI838358B (https=)
WO (1) WO2019164987A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー/エス Folr1結合剤、そのコンジュゲートおよびこれを使用する方法
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
AU2024353316A1 (en) 2023-09-26 2026-03-26 Genmab A/S Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
WO2007086083A1 (en) 2006-01-24 2007-08-02 Tecnoimage Srl Supporting frame for covering elements
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
JP6105481B2 (ja) 2010-12-06 2017-03-29 シアトル ジェネティクス,インコーポレーテッド Liv−1に対するヒト化抗体および癌治療のためのその使用
CN104220094A (zh) 2012-02-17 2014-12-17 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗lamp5抗体およびその利用
US9981046B2 (en) * 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
SG10202001468UA (en) 2014-02-17 2020-04-29 Seattle Genetics Inc Hydrophilic antibody-drug conjugates

Similar Documents

Publication Publication Date Title
JP2021513990A5 (https=)
JP2023129495A5 (https=)
JP2023082171A5 (https=)
ES2957399T3 (es) Método de síntesis de péptidos
JP2017518304A5 (https=)
IL275830A (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
JP7550768B2 (ja) 抗体-薬物コンジュゲート用のグリコシド含有ペプチドリンカー
RU2018102153A (ru) Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
JP2021521111A5 (https=)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
HUP0400974A2 (hu) Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
RU2018136778A (ru) Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы
RU2015119561A (ru) Новые конъюгаты лекарственное вещество-белок
HUT75708A (en) Neurokinine (tachykinine) antagonists
RU2018102358A (ru) Нацеленные конъюгаты ksp ингибиторов
JP2012529433A5 (https=)
RU2019105549A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RU2019134399A (ru) Конъюгат анти-trop2 антитело-лекарственное средство
TWI811246B (zh) 胜肽化合物之製造方法
TW201004647A (en) Novel dual targeting antitumoural conjugates
JP2022547434A (ja) 標的化デンドリマー複合体
WO2008078102A3 (en) Lipids and their use as non-viral delivery vehicle
AU2019350536B2 (en) Sulfomaleimide-based linkers and corresponding conjugates
JPWO2019164987A5 (https=)